Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of deferiprone delayed release tablets in Parkinson's disease
2015-004344-19Phase 2Completed
- Sponsor
- ApoPharma Inc.
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of deferiprone in Parkinson's disease (PD) (4 arms), sponsored by ApoPharma Inc. Primary endpoint: Primary efficacy criterion. Started Feb 2016; status: completed.
02
Drugs
deferiprone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-004344-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004344-19.